GlobalData expects the market for dental devices is expected to increase from being worth approximately $19.7bn last year to over $42.9bn by 2033. Image credit: Natali _ Mis / Shutterstock.

The US Food and Drug Administration (FDA) has approved a label expansion for ClaroNav’s dental navigation system, Navident EVO, to perform guided endodontic surgeries.

Navident uses volumetric medical images (CBCT) and real-time movement tracking to help dentists perform dental procedures, including placing implants. Endodontics is a dental procedure used to treat infection at the centre of a tooth, also known as a root canal.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Navident EVO can provide minimally invasive access to tooth structures during root canals. The navigation allows dentists to preserve tooth structure and have less invasive access to calcified and hidden canals. The device also increases the overall efficiency of root canal procedures by saving time in locating and accessing canals.

GlobalData expects the market for dental devices is expected to increase from being worth approximately $19.7bn last year to more than $42.9bn by 2033. The dental imaging segment is forecasted to grow from $731m to $873m over the same period.

The Navident EVO system was developed as an improvement on ClaroNav’s Navident system, which is cleared by the FDA to perform multiple guided dental surgeries, including implant cases and endodontic procedures. The EVO system was commercially launched in March 2024.

Navident EVO has a dedicated endodontic mode which can help improve the ability of the clinician to effectively detect, diagnose, and plan treatment before dynamic navigation, as per ClaroNav. The device also used AI diagnostic tools to help perform dental surgeries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The adoption of generative AI in the medical devices sector has been steadily increasing in the past few years. GobalData forecasts the AI market to reach sales of $93bn in 2023, an increase of 12% from 2022. Multiple companies are developing AI-powered imaging systems.

In February, Israel-based Magentiq Eye published data from a clinical trial showing that its AI-aided detection colonoscopy tool, Magentiq-Colo CADe increased adenoma detection by 7%, compared. Adenoma detection and removal is an important part of colorectal screening, with higher adenoma detection rates associated with a reduced risk of developing colorectal cancer.